Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10498767" target="_blank" >RIV/00179906:_____/25:10498767 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/25:00081970
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=kw5lsinJi8" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=kw5lsinJi8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/hem3.70137" target="_blank" >10.1002/hem3.70137</a>
Alternative languages
Result language
angličtina
Original language name
Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV)
Original language description
Clonal expansion of JAK2V617F-mutated hematopoietic stem cells underlies almost all cases of PV, a rare myeloproliferative neoplasm. Nevertheless, the clinical relevance of reducing the variantallele frequency (VAF) (i.e., achieving molecular response [MR] totreatment) has been disputed. Prospective trials in PV are challen-ging given the latent onset and low penetrance of major outcomessuch as thrombotic events and progression to myelofibrosis oracute myeloid leukemia. conclusion, in line with the MAJIC-PV study, these data sug-gest that the aims of PV treatment should be reconsidered to includedepletion of JAK2V617F mutated cells to modify the course of thedisease, an endpoint that can be effectively achieved with rope-ginterferon alfa-2b.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
HemaSphere
ISSN
2572-9241
e-ISSN
2572-9241
Volume of the periodical
9
Issue of the periodical within the volume
5
Country of publishing house
US - UNITED STATES
Number of pages
4
Pages from-to
e70137
UT code for WoS article
001480669500001
EID of the result in the Scopus database
2-s2.0-105004353229